Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16736757 | 0.86 | KCNH2 (0.32) | HTR2AKCNH2TMEM97SIGMAR1 | |
| SCHEMBL16736722 | 0.80 | ESR1 (0.35) | HTR2AMAP3K14KCNH2TMEM97SIGMAR1 | |
| SCHEMBL25329569 | 0.76 | ALDH1A1 (0.44) | — | |
| SCHEMBL18272081 | 0.74 | ALDH1A1 (0.42) | — | |
| SCHEMBL18587275 | 0.73 | LMNA (0.46) | — | |
| SCHEMBL29588427 | 0.73 | LMNA (0.46) | — | |
| SCHEMBL13475560 | 0.71 | TSHR (0.34) | HTR2A | |
| SCHEMBL16168707 | 0.70 | KDM4E (0.41) | — | |
| SCHEMBL4181299 | 0.70 | PTGDR2 (0.50) | — | |
| SCHEMBL16736677 | 0.69 | HTR2C (0.37) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016190871-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. (US) | 2016-12-01 | — | — | WO | claimed |
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9630896-B2 | 2,5-dialkyl-4-H/halo/ether-phenol compounds | TANSNA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630896-B2 | 2,5-dialkyl-4-H/halo/ether-phenol compounds | TANSNA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630896-B2 | 2,5-dialkyl-4-H/halo/ether-phenol compounds | TANSNA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| WO-2016190871-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016190871-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | COMT, DDT, TYR | HTR2A 521/4885MAP3K14 3333/4885KCNH2 17/4885 |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | COMT, DDT, TYR | HTR2A 521/4885MAP3K14 3333/4885KCNH2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.